224 related articles for article (PubMed ID: 26104661)
21. Immunotherapy for leukemia targeting the Wilms' tumor gene.
Yasukawa M
Leuk Lymphoma; 2001 Jul; 42(3):267-73. PubMed ID: 11699391
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
23. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
24. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.
Najima Y; Tomizawa-Murasawa M; Saito Y; Watanabe T; Ono R; Ochi T; Suzuki N; Fujiwara H; Ohara O; Shultz LD; Yasukawa M; Ishikawa F
Blood; 2016 Feb; 127(6):722-34. PubMed ID: 26702062
[TBL] [Abstract][Full Text] [Related]
25. A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.
Casey NP; Fujiwara H; Tanimoto K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
PLoS One; 2016; 11(6):e0156896. PubMed ID: 27271876
[TBL] [Abstract][Full Text] [Related]
26. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
27. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG
Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984
[TBL] [Abstract][Full Text] [Related]
28. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity.
Nagai K; Ochi T; Fujiwara H; An J; Shirakata T; Mineno J; Kuzushima K; Shiku H; Melenhorst JJ; Gostick E; Price DA; Ishii E; Yasukawa M
Blood; 2012 Jan; 119(2):368-76. PubMed ID: 22025529
[TBL] [Abstract][Full Text] [Related]
29. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
[TBL] [Abstract][Full Text] [Related]
30. WT1 as a novel target antigen for cancer immunotherapy.
Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
[TBL] [Abstract][Full Text] [Related]
31. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
[TBL] [Abstract][Full Text] [Related]
32. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
33. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
34. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
35. Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.
Kohrt HE; Müller A; Baker J; Goldstein MJ; Newell E; Dutt S; Czerwinski D; Lowsky R; Strober S
Blood; 2011 Nov; 118(19):5319-29. PubMed ID: 21868578
[TBL] [Abstract][Full Text] [Related]
36. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
Stauss HJ; Thomas S; Cesco-Gaspere M; Hart DP; Xue SA; Holler A; King J; Wright G; Perro M; Pospori C; Morris E
Blood Cells Mol Dis; 2008; 40(1):113-6. PubMed ID: 17855129
[TBL] [Abstract][Full Text] [Related]
37. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
38. WT1-targeted immunotherapy of leukaemia.
Xue S; Gao L; Gillmore R; Bendle G; Holler A; Downs AM; Tsallios A; Ramirez F; Ghani Y; Hart D; Alcock S; Tranter A; Stauss HJ; Morris E
Blood Cells Mol Dis; 2004; 33(3):288-90. PubMed ID: 15528146
[TBL] [Abstract][Full Text] [Related]
39. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
[TBL] [Abstract][Full Text] [Related]
40. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]